CMS Announces Billing Change for COVID-19 Vaccine & Monoclonal Antibody Products for MA Plan Beneficiaries

By: Kathie McDonald-McClure

Centers for Medicare & Medicaid Services (CMS) changed the Medicare payment policy for COVID-19 vaccines and monoclonal antibody products effective January 1, 2022. According to the CMS MLN Connects News for January 6, 2022, providers who administer COVID-19 vaccinations or monoclonal antibody treatments to patients enrolled in Medicare Advantage (MA) plans (as opposed to Original Medicare) are to submit claims to the MA Plan. This change applies to COVID-19 vaccinations and monoclonal antibody treatments administrated on or after January 1, 2022.  CMS states that Original Medicare will not pay these claims.

For additional information regarding COVID-19 vaccination billing, visit the CMS webpage Medicare Billing for COVID-19 Vaccine Shot Administration.

For additional information regarding monoclonal antibody treatment billing, visit the CMS webpage Monoclonal COVID-19 Infusion.

Search this Blog

Media Contact

Recent Posts

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.